As the JAK-STAT signaling pathway is central to the development of cytokine storms in severe COVID-19, baricitinib may help ameliorate its symptoms.[25] The anti-cytokine and antiviral activities of baricitinib are the primary cause of the rapid reduction in clinical and radiological recovery, viral load, inflammatory markers, and IL-6 levels from COVID-19. Here, SOAT1 is linked to COVID-19.